---
document_datetime: 2025-12-02 06:17:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord.html
document_name: eptifibatide-accord.html
version: success
processing_time: 0.1542927
conversion_datetime: 2025-12-24 05:07:37.474147
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Eptifibatide Accord

[RSS](/en/individual-human-medicine.xml/65747)

##### Authorised

This medicine is authorised for use in the European Union

eptifibatide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Eptifibatide Accord](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76230)
- [More information on Eptifibatide Accord](#more-information-on-eptifibatide-accord-1078)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Eptifibatide Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Eptifibatide Accord.

For practical information about using Eptifibatide Accord, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Eptifibatide Accord and what is it used for?

Eptifibatide Accord is a medicine used to prevent a heart attack in adults. It is used in the following groups:

- patients who have unstable angina (chest pain caused by poor blood flow to the heart, that may occur at rest or without an obvious trigger);
- patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.

Eptifibatide Accord is given with aspirin and unfractionated heparin (other medicines that prevent blood clots).

The patients most likely to benefit from a treatment with Eptifibatide Accord are those at high risk of heart attack in the three to four days after the start of acute (sudden) angina. This includes patients who are having percutaneous transluminal coronary angiography (PTCA, a type of surgery to clear the arteries supplying the heart).

The medicine contains the active substance eptifibatide.

Eptifibatide Accord is a 'generic medicine'. This means that Eptifibatide Accord is similar to a 'reference medicine' already authorised in the European Union (EU) called Integrilin.

## How is Eptifibatide Accord used?

Eptifibatide Accord should be given by a doctor who has experience in the management of heart attacks and angina and can only be obtained with a prescription. It is available as solutions for infusion (drip) and injection into a vein.

The recommended dose is 180 micrograms per kilogram body weight given as an injection into a vein as soon as possible after diagnosis. This is followed by a continuous infusion of 2.0 microgram/kg per minute which is continued for up to 72 hours, until the start of heart surgery, or until discharge from the hospital, whichever occurs first. If the patient undergoes a percutaneous coronary intervention (PCI or angioplasty, a surgical procedure that is used to unblock narrowed coronary arteries), infusion of Eptifibatide Accord can be continued for up to 24 hours after the procedure, with a maximum treatment duration of 96 hours.

Patients who have moderately reduced kidney function should receive a lower dose during the infusion. Eptifibatide Accord must not be used in patients with severe kidney problems.

## How does Eptifibatide Accord work?

Eptifibatide Accord is an inhibitor of platelet aggregation. This means that it helps to prevent cells in the blood called platelets sticking together (aggregating). This sticking together of platelets is an important step in forming a blood clot, and when it happens in the blood vessels supplying the heart it can lead to a heart attack. The active substance in Eptifibatide Accord, eptifibatide, stops the platelets aggregating by blocking a protein called glycoprotein IIb/III on their surface that helps make them sticky. This reduces the risk of a blood clot forming and helps prevent heart attacks.

## How has Eptifibatide Accord been studied?

The company provided data from the published literature on eptifibatide. No additional studies were needed as Eptifibatide Accord is a generic medicine that is given by injection and infusion into a vein and contains the same active substance as the reference medicine, Integrilin.

## What are the benefits and risks of Eptifibatide Accord?

Because Eptifibatide Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Eptifibatide Accord approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Eptifibatide Accord has been shown to be comparable to Integrilin. Therefore, the CHMP's view was that, as for Integrilin, the benefit outweighs the identified risk. The Committee recommended that Eptifibatide Accord be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Eptifibatide Accord?

A risk management plan has been developed to ensure that Eptifibatide Accord is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Eptifibatide Accord, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the [Eptifibatide Accord : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/eptifibatide-accord-epar-risk-management-plan-summary_en.pdf) .

## Other information about Eptifibatide Accord

The European Commission granted a marketing authorisation valid throughout the European Union for Eptifibatide Accord on 11 January 2016.

For more information about treatment with Eptifibatide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Eptifibatide Accord : EPAR - Summary for the public

Reference Number: EMA/20928/2016

English (EN) (101 KB - PDF)

**First published:** 18/01/2016

**Last updated:** 18/01/2016

[View](/en/documents/overview/eptifibatide-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-152)

български (BG) (130.31 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/bg/documents/overview/eptifibatide-accord-epar-summary-public_bg.pdf)

español (ES) (100.83 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/es/documents/overview/eptifibatide-accord-epar-summary-public_es.pdf)

čeština (CS) (126.99 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/cs/documents/overview/eptifibatide-accord-epar-summary-public_cs.pdf)

dansk (DA) (99.75 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/da/documents/overview/eptifibatide-accord-epar-summary-public_da.pdf)

Deutsch (DE) (101.71 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/de/documents/overview/eptifibatide-accord-epar-summary-public_de.pdf)

eesti keel (ET) (99.65 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/et/documents/overview/eptifibatide-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (131.02 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/el/documents/overview/eptifibatide-accord-epar-summary-public_el.pdf)

français (FR) (101.15 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/fr/documents/overview/eptifibatide-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (120 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/hr/documents/overview/eptifibatide-accord-epar-summary-public_hr.pdf)

italiano (IT) (99.92 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/it/documents/overview/eptifibatide-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (123.16 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/lv/documents/overview/eptifibatide-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (124.39 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/lt/documents/overview/eptifibatide-accord-epar-summary-public_lt.pdf)

magyar (HU) (121.83 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/hu/documents/overview/eptifibatide-accord-epar-summary-public_hu.pdf)

Malti (MT) (126.15 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/mt/documents/overview/eptifibatide-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (100.62 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/nl/documents/overview/eptifibatide-accord-epar-summary-public_nl.pdf)

polski (PL) (127.41 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/pl/documents/overview/eptifibatide-accord-epar-summary-public_pl.pdf)

português (PT) (100.73 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/pt/documents/overview/eptifibatide-accord-epar-summary-public_pt.pdf)

română (RO) (122.64 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/ro/documents/overview/eptifibatide-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (125.27 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/sk/documents/overview/eptifibatide-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (119.36 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/sl/documents/overview/eptifibatide-accord-epar-summary-public_sl.pdf)

Suomi (FI) (100.07 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/fi/documents/overview/eptifibatide-accord-epar-summary-public_fi.pdf)

svenska (SV) (100.18 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/sv/documents/overview/eptifibatide-accord-epar-summary-public_sv.pdf)

Eptifibatide Accord : EPAR - Risk-management-plan summary

Reference Number: EMA/20134/2016

English (EN) (43.09 KB - PDF)

**First published:** 18/01/2016

**Last updated:** 18/01/2016

[View](/en/documents/rmp-summary/eptifibatide-accord-epar-risk-management-plan-summary_en.pdf)

## Product information

Eptifibatide Accord : EPAR - Product Information

English (EN) (423.34 KB - PDF)

**First published:** 18/01/2016

**Last updated:** 02/05/2025

[View](/en/documents/product-information/eptifibatide-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-894)

български (BG) (673.01 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/bg/documents/product-information/eptifibatide-accord-epar-product-information_bg.pdf)

español (ES) (573.86 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/es/documents/product-information/eptifibatide-accord-epar-product-information_es.pdf)

čeština (CS) (589.23 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/cs/documents/product-information/eptifibatide-accord-epar-product-information_cs.pdf)

dansk (DA) (603.92 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/da/documents/product-information/eptifibatide-accord-epar-product-information_da.pdf)

Deutsch (DE) (661.41 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/de/documents/product-information/eptifibatide-accord-epar-product-information_de.pdf)

eesti keel (ET) (519.43 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/et/documents/product-information/eptifibatide-accord-epar-product-information_et.pdf)

ελληνικά (EL) (646.34 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/el/documents/product-information/eptifibatide-accord-epar-product-information_el.pdf)

français (FR) (657.2 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/fr/documents/product-information/eptifibatide-accord-epar-product-information_fr.pdf)

hrvatski (HR) (687.1 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/hr/documents/product-information/eptifibatide-accord-epar-product-information_hr.pdf)

íslenska (IS) (593.35 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/is/documents/product-information/eptifibatide-accord-epar-product-information_is.pdf)

italiano (IT) (580.01 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/it/documents/product-information/eptifibatide-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (558.52 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/lv/documents/product-information/eptifibatide-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (615.39 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/lt/documents/product-information/eptifibatide-accord-epar-product-information_lt.pdf)

magyar (HU) (683.19 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/hu/documents/product-information/eptifibatide-accord-epar-product-information_hu.pdf)

Malti (MT) (719.15 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/mt/documents/product-information/eptifibatide-accord-epar-product-information_mt.pdf)

Nederlands (NL) (610.92 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/nl/documents/product-information/eptifibatide-accord-epar-product-information_nl.pdf)

norsk (NO) (622.58 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/no/documents/product-information/eptifibatide-accord-epar-product-information_no.pdf)

polski (PL) (597.74 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/pl/documents/product-information/eptifibatide-accord-epar-product-information_pl.pdf)

português (PT) (597.24 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/pt/documents/product-information/eptifibatide-accord-epar-product-information_pt.pdf)

română (RO) (651.96 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/ro/documents/product-information/eptifibatide-accord-epar-product-information_ro.pdf)

slovenčina (SK) (712.23 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/sk/documents/product-information/eptifibatide-accord-epar-product-information_sk.pdf)

slovenščina (SL) (586.35 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/sl/documents/product-information/eptifibatide-accord-epar-product-information_sl.pdf)

Suomi (FI) (632.7 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/fi/documents/product-information/eptifibatide-accord-epar-product-information_fi.pdf)

svenska (SV) (577.63 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

02/05/2025

[View](/sv/documents/product-information/eptifibatide-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000267275 02/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Eptifibatide Accord : EPAR - All Authorised presentations

English (EN) (13.71 KB - PDF)

**First published:** 18/01/2016

**Last updated:** 18/01/2016

[View](/en/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-808)

български (BG) (33.93 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/bg/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.27 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/es/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.77 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/cs/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.14 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/da/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.23 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/de/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.8 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/et/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (31.54 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/el/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (14.1 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/fr/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.64 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/hr/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.04 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/is/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.41 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/it/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (31.52 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/lv/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (28.83 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/lt/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (20.5 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/hu/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.26 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/mt/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.23 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/nl/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (14.31 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/no/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (31.05 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/pl/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.68 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/pt/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (30.91 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/ro/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.65 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/sk/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.12 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/sl/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.1 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/fi/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.3 KB - PDF)

**First published:**

18/01/2016

**Last updated:**

18/01/2016

[View](/sv/documents/all-authorised-presentations/eptifibatide-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Eptifibatide Accord Active substance eptifibatide International non-proprietary name (INN) or common name eptifibatide Therapeutic area (MeSH) Myocardial Infarction Anatomical therapeutic chemical (ATC) code B01AC16

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.

Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.

Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty).

## Authorisation details

EMA product number EMEA/H/C/004104

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 19/11/2015 Marketing authorisation issued 11/01/2016 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Eptifibatide Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.11 KB - PDF)

**First published:** 25/02/2025

**Last updated:** 02/05/2025

[View](/en/documents/procedural-steps-after/eptifibatide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Eptifibatide Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (111.32 KB - PDF)

**First published:** 20/02/2019

**Last updated:** 21/04/2023

[View](/en/documents/procedural-steps-after/eptifibatide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Eptifibatide Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/851528/2015

English (EN) (1022.1 KB - PDF)

**First published:** 18/01/2016

**Last updated:** 18/01/2016

[View](/en/documents/assessment-report/eptifibatide-accord-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Eptifibatide Accord

Adopted

Reference Number: EMA/CHMP/721224/2015

English (EN) (69.39 KB - PDF)

**First published:** 20/11/2015

**Last updated:** 20/11/2015

[View](/en/documents/smop-initial/chmp-summary-opinion-eptifibatide-accord_en.pdf)

#### News on Eptifibatide Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2015) 20/11/2015

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Eptifibatide Accord : EPAR - Product information - tracked changes

English (EN) (152.81 KB - DOCX)

**First published:** 02/05/2025

[View](/en/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-984)

български (BG) (191.26 KB - DOCX)

**First published:**

02/05/2025

[View](/bg/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_bg.docx)

español (ES) (150.16 KB - DOCX)

**First published:**

02/05/2025

[View](/es/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_es.docx)

čeština (CS) (144.69 KB - DOCX)

**First published:**

02/05/2025

[View](/cs/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (147.82 KB - DOCX)

**First published:**

02/05/2025

[View](/da/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (153.62 KB - DOCX)

**First published:**

02/05/2025

[View](/de/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (122.04 KB - DOCX)

**First published:**

02/05/2025

[View](/et/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (171.38 KB - DOCX)

**First published:**

02/05/2025

[View](/el/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_el.docx)

français (FR) (151.66 KB - DOCX)

**First published:**

02/05/2025

[View](/fr/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (157.66 KB - DOCX)

**First published:**

02/05/2025

[View](/hr/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (142.91 KB - DOCX)

**First published:**

02/05/2025

[View](/is/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_is.docx)

italiano (IT) (147.36 KB - DOCX)

**First published:**

02/05/2025

[View](/it/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (137.75 KB - DOCX)

**First published:**

02/05/2025

[View](/lv/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (132.7 KB - DOCX)

**First published:**

02/05/2025

[View](/lt/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (145.08 KB - DOCX)

**First published:**

02/05/2025

[View](/hu/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (155.9 KB - DOCX)

**First published:**

02/05/2025

[View](/mt/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (136.3 KB - DOCX)

**First published:**

02/05/2025

[View](/nl/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (155.22 KB - DOCX)

**First published:**

02/05/2025

[View](/no/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_no.docx)

polski (PL) (160.47 KB - DOCX)

**First published:**

02/05/2025

[View](/pl/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_pl.docx)

português (PT) (133.64 KB - DOCX)

**First published:**

02/05/2025

[View](/pt/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_pt.docx)

română (RO) (179.92 KB - DOCX)

**First published:**

02/05/2025

[View](/ro/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (146.92 KB - DOCX)

**First published:**

02/05/2025

[View](/sk/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (152.86 KB - DOCX)

**First published:**

02/05/2025

[View](/sl/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (150.55 KB - DOCX)

**First published:**

02/05/2025

[View](/fi/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (147.9 KB - DOCX)

**First published:**

02/05/2025

[View](/sv/documents/product-information-tracked-changes/eptifibatide-accord-epar-product-information-tracked-changes_sv.docx)

#### More information on Eptifibatide Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/05/2025

## Share this page

[Back to top](#main-content)